Aga Khan University

aku.edu

Total trials

317

Active

41

Phase 3

30

Total enrollment

5,763,509

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 18 of 18 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Acotiamide1
itopride1
Enhanced Recovery After Surgery1
Control1
Methylprednisolone1
Saline2
MMS Plus1
sodium acetate group will receive sodium acetate in the neonatal PN.1
sodium chloride group will receive sodium chloride in the neonatal PN.1
Vitamin D2
Oral Vancomycin1
VE8181
Ketamine1
Nalbuphine1
Paracetamol1
LMW Heparin 5000 U/ML-Aspirin 75 MG1
LMW Heparin 5000 U/ML1
Benazir Nashonuma Program1

Next readouts

  • 2025-04-30
  • 2025-05-10
  • 2025-06-30
  • 2025-12
  • 2025-12-20
  • 2026-06-30
  • 2026-08-01
  • 2026-08-31
  • 2026-12
  • 2026-12-01

Top conditions

  • Anemia10
  • Hypertension10
  • Malnutrition9
  • Stunting9
  • Pregnancy7
  • Breast Cancer6
  • Pneumonia5
  • Polio5

Frequently asked questions about Aga Khan University

How many clinical trials does Aga Khan University have on ClinicalTrials.gov?
Aga Khan University is listed as the lead sponsor on 317 clinical trials in ClinicalTrials.gov, 41 of which are currently active (recruiting, enrolling, or ongoing).
How many of Aga Khan University's trials are in Phase 3?
30 of Aga Khan University's trials are in Phase 3, spread across 18 active drug programs.
What therapeutic areas does Aga Khan University focus on?
Aga Khan University's most-studied conditions on ClinicalTrials.gov are Anemia, Hypertension, Malnutrition, Stunting, Pregnancy.
When are Aga Khan University's next clinical trial readouts?
Aga Khan University has 10 upcoming primary-completion readouts tracked here; the soonest is “Effect of Methylprednisolone on Systemic Inflammatory Response During Pediatric Congenital Open-Heart Surgery”, expected around 2025-04-30.